Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A

被引：54

作者：

Bartoli, M ^{[1
]}

Roudaut, C ^{[1
]}

Martin, S ^{[1
]}

Fougerousse, F ^{[1
]}

Suel, L ^{[1
]}

Poupiot, J ^{[1
]}

Gicquel, E ^{[1
]}

Noulet, F ^{[1
]}

Danos, O ^{[1
]}

Richard, I ^{[1
]}

机构：

[1] Genethon, CNRS, UMR8115, F-91000 Evry, France

来源：

MOLECULAR THERAPY | 2006年 / 13卷 / 02期

关键词：

limb girdle muscular dystrophy type 2A; gene transfer; calpain; 3; AAV; muscle;

D O I：

10.1016/j.ymthe.2005.09.017

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Calpainopathy (limb-girdle muscular dystrophy type 2A, LGMD2A) is a recessive muscular disorder caused by deficiency in the calcium-dependent cysteine protease calpain 3. To date, no treatment exists for this disease. We evaluated the potential of recombinant adeno-associated virus (rAAV) vectors for gene therapy in a murine model for LGMD2A. To drive the expression of calpain 3, we used rAAV2/1 pseudotyped vectors and muscle-specific promoters to avoid calpain 3 cell toxicity. We report efficient and stable transgene expression in muscle with restoration of the proteolytic activity and without evident toxicity. In addition, calpain 3 was correctly targeted to the sarcomere. Moreover, its presence resulted in improvement of the histological features and in therapeutic efficacy at the physiological levels, including correction of atrophy and full rescue of the contractile force deficits. Our results establish the feasibility of AAV-mediated calpain 3 gene transfer as a therapeutic approach.

引用

页码：250 / 259

页数：10

共 38 条

[21] KARPATI G, 2001, DISORDERS VOLUNTARY, pR14
[22] Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro
Kramerova, I
Kudryashova, E
Spencer, MJ
[J]. HUMAN MOLECULAR GENETICS, 2004, 13 (13) : 1373 - 1388
[23] Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences
Li, XY
Eastman, EM
Schwartz, RJ
Draghia-Akli, R
[J]. NATURE BIOTECHNOLOGY, 1999, 17 (03) : 241 - 245
[24] LI ZL, 1991, J BIOL CHEM, V266, P6562
[25] Calpainopathy - A survey of mutations and polymorphisms
Richard, I
Roudaut, C
Saenz, A
Pogue, R
Grimbergen, JEMA
Anderson, LVB
Beley, C
Cobo, AM
de Diego, C
Eymard, B
Gallano, P
Ginjaar, HB
Lasa, A
Pollitt, C
Topaloglu, H
Urtizberea, JA
de Visser, M
van der Kooi, A
Bushby, K
Bakker, E
de Munain, AL
Fardeau, M
Beckmann, JS
[J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (06) : 1524 - 1540
[26] MUTATIONS IN THE PROTEOLYTIC-ENZYME CALPAIN-3 CAUSE LIMB-GIRDLE MUSCULAR-DYSTROPHY TYPE-2A
RICHARD, I
BROUX, O
ALLAMAND, V
FOUGEROUSSE, F
CHIANNILKULCHAI, N
BOURG, N
BRENGUIER, L
DEVAUD, C
PASTURAUD, P
ROUDAUT, C
HILLAIRE, D
PASSOSBUENO, MR
ZATZ, M
TISCHFIELD, JA
FARDEAU, M
JACKSON, CE
COHEN, D
BECKMANN, JS
[J]. CELL, 1995, 81 (01) : 27 - 40
[27] Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IκBα/nuclear factor κB pathway perturbation in mice
Richard, I
Roudaut, C
Marchand, S
Baghdiguian, S
Herasse, M
Stockholm, D
Ono, Y
Suel, L
Bourg, N
Sorimachi, H
Lefranc, G
Fardeau, M
Sébille, A
Beckmann, JS
[J]. JOURNAL OF CELL BIOLOGY, 2000, 151 (07) : 1583 - 1590
[28] Long-term pharmacologically regulated expression of erythropoietin in,primates following AAV-mediated gene transfer
Rivera, VM
Gao, GP
Grant, RL
Schnell, MA
Zoltick, PW
Rozamus, LW
Clackson, T
Wilson, JM
[J]. BLOOD, 2005, 105 (04) : 1424 - 1430
[29] Factors influencing recombinant adeno-associated virus production
Salvetti, A
Orève, S
Chadeuf, G
Favre, D
Cherel, Y
Champion-Arnaud, P
David-Ameline, J
Moullier, P
[J]. HUMAN GENE THERAPY, 1998, 9 (05) : 695 - 706
[30] Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
Snyder, RO
Miao, CH
Patijn, GA
Spratt, SK
Danos, O
Nagy, D
Gown, AM
Winther, B
Meuse, L
Cohen, LK
Thompson, AR
Kay, MA
[J]. NATURE GENETICS, 1997, 16 (03) : 270 - 276

← 1 2 3 4 →